Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
MolecuLight Successfully Completes SOC 2 Type II Audit
The SOC 2 Type II audit verifies that MolecuLight's internal controls, policies, and procedures conform to stringent security and operational standards that demonstrate the suitability of the design and operating effectiveness of its controls relevant to SOC 2 security criteria. SOC 2 defines criteria for managing customer data based on five "Trust Service Criteria"—security, availability, processing integrity, confidentiality, and privacy. Certification demonstrates a company's…
PR Newswire
12/12/2023
Sharps Containers Market in Europe to Pierce US$ 262.2 Million by 2034: Safety…
Request Exclusive Sample Report: Sharp Container Industry Forecast in Europe Strategic Insights: https://www.futuremarketinsights.com/reports/sample/rep-gb-18467 Request Exclusive Sample Report: Sharp Container Industry Forecast in Europe Strategic Insights:https://www.futuremarketinsights.com/reports/sample/rep-gb-18467 A sharps container is specially designed for disposing of medical waste, including needles. To prevent sharps injuries caused by needles or other sharp devices,...
PR Newswire
11/12/2023
Neurotrophic Keratopathy Market to Grow Rapidly at a CAGR of 15.4% by 2032…
Neurotrophic Keratopathy Market Report Key Takeaways Neurotrophic Keratopathy Market Report Key Takeaways Discover which therapies are expected to grab the major neurotrophic keratopathy market share @Neurotrophic Keratopathy Market Report Neurotrophic Keratopathy Overview Neurotrophic keratopathy, referred to as neurotrophic keratitis or trigeminal neuropathic keratopathy, is a rare degenerative eye condition affecting the cornea. The disease manifests as a reduction or...
PR Newswire
11/12/2023
Press Release: Statement on FTC challenge to proposed license agreement with…
Statement on FTC challenge to proposed license agreement with Maze TherapeuticsParis, December 11, 2023. Sanofi is disappointed with the Federal Trade Commission's announcement that it is seeking a preliminary injunction against a proposed licensing agreement between Sanofi and Maze Therapeutics. The agreement, announced on May 1, 2023, is for MZE001, a glycogen synthase 1 (GYS1) inhibitor program that has completed Phase 1 and is in development for Pompe Disease, a rare, inherited and...
Nasdaq GlobeNewswire
11/12/2023
Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating…
Press ReleaseStockholm, Sweden, December 11, 2023 As of November 24, 2023, median relapse-free survival (mRFS) stood at 30.4 months Median overall survival (mOS) was not reached, with the majority of patients (14/20) still aliveReduction in measurable residual disease (MRD) and induction of immune responses correlate with RFS and OS benefit, confirming vididencel mechanism of actionVirtual KOL event with principal investigator to discuss new ASH data on Thursday,...
Nasdaq GlobeNewswire
11/12/2023
Pharmaceutical Glass Tubing Market to Reach US$ 11.2 Billion by 2030, Rising at…
Secondly, the increasing research and development activities in the pharmaceuti,cal industry are also driving market growth. Pharmaceutical companies are investing heavily in R&D to develop innovative drugs and therapies. Glass tubing plays a crucial role in the packaging and delivery of these drugs, thus increasing the demand for pharmaceutical glass tubing. Secondly, the increasing research and development activities in the pharmaceuti,cal industry are also driving market growth....
PR Newswire
11/12/2023
The European Commission granted Marketing Authorisation for Vueway®…
Vueway® (gadopiclenol) is a new highly stable, macrocyclic gadolinium-based contrast agent (GBCA) with the highest values of longitudinal (R1) relaxivity among all the GBCAs approved for use in the EU and the USA. 4 Thanks to its high relaxivity, large, multicenter, adequate and well controlled clinical studies have shown that Vueway® provides similar diagnostic efficacy at half the dose of gadobutrol, a GBCA routinely used in clinical practice in the EU. 1,2 Vueway ®(gadopiclenol) is a new...
PR Newswire
11/12/2023
Groupe Casino: Extension of the accelerated safeguard period
Extension of the accelerated safeguard period Paris, 11 December 2023The Casino Group announces that, in a ruling handed down today, the Paris Commercial Court has extended for a further two months (from 25 December 2023 to 25 February 2024) the accelerated safeguard procedures initiated on 25 October 2023 for Casino, Guichard-Perrachon and its six subsidiaries concerned 1. ***This press release was prepared solely for information purposes and should not be construed as, nor...
Nasdaq GlobeNewswire
11/12/2023
Disclosure of notification received from BNP Paribas Asset Management SA
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 11 December 2023 – 6PM CET Disclosure of notification received from BNP Paribas Asset Management SA Fagron received a notification pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies from BNP Paribas Asset Management SA. Notification of BNP Paribas Asset Management SAOn 8 December 2023, Fagron received a notification that the shareholding of BNP Paribas...
Nasdaq GlobeNewswire
11/12/2023
Carbios praised by French President at two-year anniversary of France 2030
PRESS RELEASE Carbios praised by French President at two-year anniversary of France 2030 Clermont-Ferrand (France), December 11, 2023 (6:00 PM CET). Carbios(Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, was one of eight beneficiaries selected to present the progress of its industrial project in the presence of the President of the French Republic on the...
Nasdaq GlobeNewswire
11/12/2023
Tech-infused Soles and Fit-conscious Consumers Fuel Shoe Insoles Market Growth…
Unlock valuable insights - Get your PDF sample report today! https://www.futuremarketinsights.com/reports/sample/rep-gb-18621 Unlock valuable insights - Get your PDF sample report today!https://www.futuremarketinsights.com/reports/sample/rep-gb-18621 With increasing awareness about the benefits of physical exercise, like running, the need for performance-enhancing accessories in the footwear industry is experiencing a tremendous surge. Shoe insoles, one of them, are in great...
PR Newswire
11/12/2023
Guerbet announces marketing authorisation approval of Elucirem™ (Gadopiclenol)…
Born of Guerbet innovation, Elucirem™ (Gadopiclenol) is the gadolinium-based contrast agent with the highest relaxivity, in comparison to other available gadolinium-based contrast agents (GBCA). In the European Union, Elucirem is indicated in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging (MRI) to improve detection and visualization of pathologies with disruption of the blood-brain-barrier (BBB) and/or abnormal vascularity of: "Elucirem™...
PR Newswire
11/12/2023
Acne Treatment Market Size to Reach USD 15,183.2 Million By 2032| Precedence…
The Europe acne treatment market size surpassed USD 2,592.5 million in 2022 and is estimated to hit around USD 4,115.1 million by 2032, growing at a CAGR of 4.9% during the future period 2023 to 2032. TheEuropeacne treatment market size surpassedUSD 2,592.5 millionin 2022 and is estimated to hit aroundUSD 4,115.1 millionby 2032, growing at a CAGR of 4.9% during the future period 2023 to 2032. TheAsia Pacificacne treatment market size was evaluated atUSD 1,750.9 millionin...
PR Newswire
11/12/2023
Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2…
"It is encouraging to see positive initial safety results in various combination studies of ORSERDU, along with promising preliminary efficacy data in these trials," said Hope Rugo, MD, professor of medicine, Division of Hematology and Oncology at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center. "We look forward to learning more about ORSERDU's role in combination settings and its potential across the spectrum of metastatic breast…
PR Newswire
11/12/2023
Immunology Market Size to Grow USD 102790 Million by 2029 at a CAGR of 6.5% |…
Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-20H6044/Global_Immunology Claim Your Free Sample Now: https://reports.valuates.com/request/sample/QYRE-Auto-20H6044/Global_Immunology Major Factors driving the growth of Immunology Market: A number of factors are coming together to drive the strong growth of the immunology market. The need for immunological interventions is growing as a result of advancements in immunotherapy, particularly in...
PR Newswire
11/12/2023
Hoteliers Cater to Convenience-Seeking Guests, Driving Minibar Refrigerators…
Over the next ten years, the worldwide demand for minibar refrigerators is anticipated to rise at a CAGR of 3.7% over the forecast period. By 2034, the global minibar refrigerator industry value is expected to reach US$ 518.6 million. Over the next ten years, the worldwide demand for minibar refrigerators is anticipated to rise at aCAGR of 3.7%over the forecast period. By 2034, the global minibar refrigerator industry value is expected to reach US$ 518.6 million . Unlock valuable...
PR Newswire
11/12/2023
Bioretec Ltd's schedule for financial reporting in 2024 and updates in the…
The updated disclosure policy is available on the company's web pages at https://bioretec.com/investors/investors-in-english/investor-relations/disclosure-policy The updated disclosure policy is available on the company's web pages athttps://bioretec.com/investors/investors-in-english/investor-relations/disclosure-policy Bioretec Ltd's schedule for financial reporting in 2024 In 2024, Bioretec will publish the following financial reports: The Annual Report includes the report of...
PR Newswire
11/12/2023
Nephrology and Urology Devices Market to Reach $47.8 Billion, Globally, by 2032…
Request Sample of the Report on Nephrology and Urology Devices Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/420 Request Sample of the Report on Nephrology and Urology Devices Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/420 Prime determinants of growth Increase in prevalence of kidney and urological disorders such as chronic kidney disease, urinary tract infections, kidney stones, & urologic cancers; surge in...
PR Newswire
11/12/2023
Aptamers Market Size Worth USD 925 million by 2035 | Roots Analysis
The global aptamers market size was estimated to be USD 30 million in 2023 and is expected to reach USD 925 million by 2035, growing at a compounded annual growth rate of 33% during the forecast period 2024-2035. The globalaptamers market size was estimated to be USD 30 million in 2023 and is expected to reach USD 925 million by 2035, growing at a compounded annual growth rate of 33% during the forecast period 2024-2035. Aptamers refer to the single-stranded DNA and RNA molecules that...
PR Newswire
11/12/2023
Calliditas Receives Notice of Allowance for United States Patent Application…
Calliditas intends to file corresponding patent applications in additional territories around the world, including Europe and China. Calliditas intends to file corresponding patent applications in additional territories around the world, includingEuropeandChina. "When issued, our new patent will significantly strengthen TARPEYO's intellectual property protection, further improving its unique value proposition, and providing a basis for an active program of extending patent protection...
PR Newswire
11/12/2023
Genome Editing Market Size and Share to Surpass USD 14.5 billion by 2035 | Roots…
The global genome editing market is estimated to be worth over USD 3.5 billion in 2023 and is poised to reach USD 14.5 billion by 2035, it is anticipated to grow at a compound annual growth rate (CAGR) of 12.6% during the forecast period (2023-2035). The global genome editing market is estimated to be worth overUSD 3.5 billionin 2023 and is poised to reachUSD 14.5 billionby 2035, it is anticipated to grow at a compound annual growth rate (CAGR) of 12.6% during the forecast period...
PR Newswire
11/12/2023
Inovalon Applauded by Frost & Sullivan for Improving Healthcare Delivery…
The cloud-based Inovalon ONE Platform provides SaaS solutions leveraging the company's national-scale connectivity, real-time primary source data, and advanced analytics to provide actionable insights that inform and expedite patient care and business strategies. Using Inovalon's MORE2 Registry®, the nation's largest healthcare dataset originating from longitudinally matched and primary source data, the platform helps achieve data integration, compliance, and security. Additionally, Inovalon's…
PR Newswire
11/12/2023
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 11 December 2023– On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under…
Nasdaq GlobeNewswire
11/12/2023
AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in…
Novel Non-surgical Intradermal Treatment for Basel Cell Carcinoma COSA MESA, Calif., Dec.11, 2023(GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced completion of their first trial administering AIV001 (axitinib) to patients diagnosed with basal cell carcinoma (BCC) tumors. AIV001 is AiViva's novel intradermally administered product designed for local, prolonged treatment effect for dermatological conditions.The phase 1/2 multicenter,...
Nasdaq GlobeNewswire
11/12/2023
Altri Comunicati
